|3.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
|5.||Hematologic Neoplasms (Hematological Malignancy)
|1.||Tallman, Martin S: 41 articles (11/2015 - 01/2002)|
|2.||Sanz, Miguel A: 38 articles (11/2015 - 05/2002)|
|3.||Lo-Coco, Francesco: 37 articles (12/2015 - 10/2002)|
|4.||Chen, Zhu: 31 articles (12/2015 - 02/2002)|
|5.||Chen, Sai-Juan: 23 articles (06/2015 - 02/2002)|
|6.||Miller, Wilson H: 22 articles (04/2014 - 01/2002)|
|7.||Kantarjian, Hagop: 21 articles (05/2015 - 05/2003)|
|8.||Grimwade, David: 20 articles (11/2015 - 08/2002)|
|9.||Breccia, Massimo: 19 articles (09/2015 - 02/2002)|
|10.||Montesinos, Pau: 19 articles (05/2014 - 01/2007)|
|1.||Tretinoin (Retinoic Acid)FDA LinkGeneric
12/01/2015 - "Although differentiation therapy with all-trans retinoic acid (ATRA) induces complete remission in most acute promyelocytic leukemia (APL) patients, it is associated with organ toxicity. "
04/01/2014 - "The best characterized clinical application of differentiation therapy is the use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia (APL), which markedly improved the outcome of this disease. "
07/01/2013 - "All-trans retinoic acid (ATRA) induces clinical remission in most acute promyelocytic leukemia (APL) patients by inducing terminal differentiation of APL cells toward mature granulocytes. "
09/01/2011 - "All-trans retinoic acid (ATRA) induces complete remission in most cases of acute promyelocytic leukemia. "
07/01/2005 - "The success of all-trans retinoic acid in the treatment of acute promyelocytic leukemia indicates that transcription therapy can be highly effective and safe. "
|2.||arsenic trioxide (Trisenox)FDA Link
01/01/2011 - "Arsenic trioxide (ATO), a natural product that has improved the prognosis of acute promyelocytic leukemia (APL) from highly fatal to highly curable, has also been proven to be effective in treating BL cell lines through multiple pathways in our study. "
11/20/2014 - "Arsenic trioxide (ATO) is a highly effective agent for the treatment of acute promyelocytic leukemia (APL). "
01/01/2013 - "Arsenic trioxide (As2O3) is a highly effective agent for treatment of acute promyelocytic leukemia (APL). "
08/11/2011 - "Arsenic trioxide (As₂O₃) is a highly effective treatment for patients with refractory/relapsed acute promyelocytic leukemia (APL), but resistance to As₂O₃ has recently been seen. "
05/01/2011 - "Arsenic trioxide (ATO) has been proven to be highly effective in adults with newly diagnosed or relapsed acute promyelocytic leukemia (APL). "
|3.||Aligeron (AS 2)IBA
06/15/2003 - "Although parenteral administration of As(2)O(3) is highly effective in the treatment of acute promyelocytic leukemia, cardiac toxicity has been reported. "
09/15/1999 - "Low concentrations of As(2)O(3) (</=1 micromol/L) induce long-lasting remission in patients with acute promyelocytic leukemia (APL) without significant myelosuppressive side effects. "
07/13/2010 - "As(2)O(3) cures acute promyelocytic leukemia (APL) by initiating PML/RARA oncoprotein degradation, through sumoylation of its PML moiety. "
12/01/2007 - "Differentiation Syndrome (DS) is a treatment complication which can occur in patients treated with acute promyelocytic leukemia (APL) with all transretinoic acid (ATRA) or As(2)O(3), and is characterized by enhanced leukocyte transmigration. "
04/01/2004 - "As trioxide (As(2)0(3)) has been recently used as a mitochondria-targeting drug in acute promyelocytic leukemia. "
|4.||retinoic acid receptor alphaIBA
08/01/1997 - "Reverse-transcription polymerase chain reaction (RT-PCR) of the PML/RAR alpha fusion gene may predict relapse in acute promyelocytic leukemia (APL) patients in hematologic complete remission (CR). "
03/01/1996 - "To determine objective indices for differentiation which can be used for judging complete remission, we treated 18 patients with acute promyelocytic leukemia, and performed sequential analysis of bone marrow, karyotype, RAR alpha gene rearrangement and PML-RAR alpha fusion gene transcript. "
02/15/1994 - "Fifty-one patients subsequently were found to have the PML/RAR-alpha gene rearrangement indicative of acute promyelocytic leukemia, and 44 of these patients achieved complete remission (86%; 95% Cl, 76% to 96%). "
12/15/1993 - "In this study, 9 patients (pts) with acute promyelocytic leukemia (APL) in long-term remission for 4 to 12 years were analyzed for the presence of MRD by RT-PCR amplification of the specific PML/RAR-alpha fusion gene. "
04/01/1997 - "Absence of detectable PML-RAR alpha fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia."
07/01/2008 - "The ancient drug, arsenic, has remarkable efficacy in the treatment of relapsed acute promyelocytic leukemia (APL) and this success has led to exploration of its use in other malignancies. "
02/01/2005 - "Arsenic, a natural substance that has been used as a drug for over 2000 years, has been revived because of its remarkable therapeutic efficacy in patients with acute promyelocytic leukemia (APL). "
02/05/2010 - "Arsenic is ubiquitously present in the environment; it is a known human carcinogen and paradoxically it is also a successful drug for the clinical remission of acute promyelocytic leukemia (APL). "
06/01/2001 - "Arsenic oxide (As2O3) has recently been reported to induce remission in a high percentage of patients with acute promyelocytic leukemia (APL). "
05/01/2013 - "Although arsenic is effective in the treatment of acute promyelocytic leukemia (APL), as a well-known environmental toxicant, the side effects of arsenic treatment and arsenic methylation metabolism of the patients are rarely reported. "
|6.||promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA
12/01/2003 - "[Improved RT-PCR for detection of PML/RARalpha fusion gene in rapid diagnosis of acute promyelocytic leukemia]."
07/01/1996 - "Improved rapid detection of the PML/RARalpha fusion gene in acute promyelocytic leukemia."
01/01/2001 - "Acute promyelocytic leukemia (APL) patients with t(15;17)(PML/RARalpha positive) achieve remission upon t-RA treatment, whereas patients with t(11;17)(PLZF/RARalpha positive) do not. "
07/01/2003 - "This study investigated the clinical characteristics and prognostic relevance of CD34 expression in 47 patients with acute promyelocytic leukemia (APL), showing t(15;17) or PML/RARalpha. "
01/01/2001 - "To study the relationship between the expression level of the PML-RARalpha fusion transcripts and the clinical status and efficiency of the therapy in acute promyelocytic leukemia (APL) patients, we applied a very sensitive and specific real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) system to quantify the dose of PML-RARalpha fusion transcripts in a series of APL patients at distinct disease stages. "
|7.||Cytarabine (Cytosar-U)FDA LinkGeneric
12/20/2006 - "Is cytarabine useful in the treatment of acute promyelocytic leukemia? "
02/14/1970 - "[Abnormalities of the erythropoiesis at the beginning of remission in acute promyelocytic leukemia treated with arabinoside-cytosine]."
10/01/2014 - "A prospective, observational study of added medium-dose cytosine arabinoside versus As2O3 for elderly patients with acute promyelocytic leukemia."
06/01/2005 - "The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL). "
03/01/2011 - "There are very limited data reported about the role of cytarabine (Ara-C) in childhood acute promyelocytic leukemia (APL). "
07/01/1996 - "Retinoids are differentiating agents that have been used successfully for the treatment of acute promyelocytic leukemia. "
03/01/2004 - "Thus, disruption of targeted pathways, together with specific retinoids, might be an effective therapeutic treatment for acute promyelocytic leukemia."
04/01/2002 - "While retinoids have demonstrated therapeutic efficacy in the treatment of acute promyelocytic leukemia, their spectrum of activity remains limited. "
02/01/2013 - "Therefore, research strategies that seek to further sensitize cells to retinoids and extend the range of retinoid-affected myeloid malignancies beyond acute promyelocytic leukemia (APL) are key investigative avenues. "
12/01/2012 - "Acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) and PML-RARa rearrangement, with good response to treatment with retinoids. "
|9.||Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric
11/01/2002 - "Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up."
05/05/2011 - "From July 1993 to May 2000, 807 genetically proven newly diagnosed acute promyelocytic leukemia patients received ATRA plus idarubicin as induction, followed by 3 intensive consolidation courses. "
10/28/2010 - "After the identification of discrete relapse-risk categories in patients with acute promyelocytic leukemia (APL) receiving all-trans retinoic and idarubicin (AIDA)-like therapies, the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) designed a protocol for newly diagnosed APL (AIDA-2000) in which postremission treatment was risk-adapted. "
04/01/1990 - "Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA."
09/01/2007 - "Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?"
|10.||gemtuzumab (gemtuzumab ozogamicin)FDA Link
04/01/2008 - "[Gemtuzumab ozogamicin successfully induced molecular remission in relapsed therapy-related acute promyelocytic leukemia]."
09/01/2007 - "Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia."
04/01/2010 - "[Molecular remission induced by gemtuzumab ozogamicin in an elderly patient with relapsed acute promyelocytic leukemia]."
12/01/2002 - "Gemtuzumab ozogamicin-based regimens may be particularly worthy of study in patients with acute promyelocytic leukemia. "
02/01/2011 - "Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy."
|1.||Drug Therapy (Chemotherapy)
02/01/2015 - "ATRA induces complete remission in patients with acute promyelocytic leukemia, but it cannot completely eliminate the leukemic clone and to be effective it should be combined with chemotherapy. "
12/01/2012 - "The optimal maintenance therapy for patients with acute promyelocytic leukemia (APL) who achieved complete remission (CR) and complete consolidation chemotherapy is still controversial. "
07/01/2004 - "All-transretinoic acid (ATRA) and chemotherapy has improved complete remission rates and disease free survival in acute promyelocytic leukemia (APL). "
01/01/2001 - "INF + ATRA during remission maintained a long first complete remission (median 18 months) in patients with primary AML after small-volume drug therapy, led to long first and second complete remissions (median 12 months) in patients with resistant AML, and induced and maintained molecular remissions in patients with acute promyelocytic leukemia."
01/01/2001 - "Three-day INF + ATRA course was administered every 3 months to 22 patients with AML from high risk group (impossibility of drug therapy during the first complete remission, resistant forms of AML, relapses, secondary AML, acute promyelocytic leukemia after attaining molecular remission). "
01/01/2015 - "The patient confirmed acute promyelocytic leukemia three years ago and the disease was in remission after treatment. "
08/15/2002 - "Second malignancy after treatment of acute promyelocytic leukemia: experience of GIMEMA trials. "
01/01/2014 - "Therapy-related myeloid neoplasm after treatment for acute promyelocytic leukemia (APL) is a relatively infrequent but severe complication. "
01/01/2014 - "TRIP11-PDGFRB fusion in a patient with a therapy-related myeloid neoplasm with t(5;14)(q33;q32) after treatment for acute promyelocytic leukemia."
12/01/2013 - "Clinical characteristics of a case with secondary acute promyelocytic leukemia (APL) were summarized and 10 cases of secondary leukemia after treatment for HLH from literature were analyzed. "
02/01/2014 - "The patients with acute promyelocytic leukemia hospitalized in our hospital from January 2011 to December 2012 were observed and all achieved complete remission after remission induction therapy. "
07/01/2014 - "It has been demonstrated that this drug is effective against all stages of acute promyelocytic leukemia, including for remission induction of relapsed cases, or as first-line treatment. "
03/01/2007 - "Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome."
03/01/1996 - "The therapeutic effect of all-trans-RA (ATRA) in induction of remission for acute promyelocytic leukemia (APL) has largely been proved, and this has, over the past 10 years, greatly stimulated research on oncogenesis and RA-regulated differentiation pathways. "
05/01/1992 - "[Auer rods-positive neutrophils observed at diagnosis increased after remission induction in patient with acute promyelocytic leukemia]."
|4.||Stem Cell Transplantation
01/01/2005 - "To retrospectively determine the outcome of acute promyelocytic leukemia (APL) patients who underwent autologous or allogeneic stem-cell transplantation (SCT) during second complete remission. "
10/01/2003 - "Early relapse after non myeloablative allogeneic stem cell transplantation in a patient with acute promyelocytic leukemia in complete molecular remission."
09/01/2010 - "Autologous stem cell transplantation for patients with acute promyelocytic leukemia in second molecular remission."
06/01/2006 - "Autologous and allogeneic stem cell transplantation in first remission are also valid alternatives, but the value of low-dose maintenance treatment seems confined to acute promyelocytic leukemia. "
05/01/2004 - "Prolonged molecular remission after autologous stem cell transplantation in relapsed acute promyelocytic leukemia."
|5.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
11/01/1998 - "Role of autologous bone marrow transplantation as consolidation therapy in acute promyelocytic leukemia patients in complete remission."
07/01/1989 - "Leukemic relapse in host cells almost 7 years after bone marrow transplantation for acute promyelocytic leukemia in first complete remission."
08/01/1997 - "Autologous bone marrow transplantation in a child with acute promyelocytic leukemia in second remission."
10/01/1995 - "We described a case of acute promyelocytic leukemia with O blood type who received bone marrow transplantation during a second remission from his HLA identical, B blood type sibling. "
08/01/2001 - "The role of bone marrow transplantation in acute promyelocytic leukemia."